Probiodrug Transfers its CDK9 Inhibitor Program to AstraZeneca

Home › Probiodrug Transfers its CDK9 Inhibitor Program to AstraZeneca

Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca .

18.06	Potential Tropical Cyclone One Graphics
18.06	Potential Tropical Cyclone One Public Advisory Number 3A
18.06	Summary for Potential Tropical Cyclone One (AT1/AL012024)
18.06	Post Office sabotaged Horizon probe, says investigator
18.06	Atlantic Tropical Weather Outlook
18.06	Eastern North Pacific Tropical Weather Outlook
18.06	Farm Progress America, June 18, 2024
18.06	Farm Progress America, June 18, 2024
More »

je.st